Zai Lab registers Phase 3 trial for ZL-1310 in lung cancer and real-world KarXT study in China

Zai Lab posted two new clinical trial registrations this week, one interventional and one observational.

• ZL-1310, described as a DLL3 antibody-drug conjugate (ADC)¹, is set for a Phase 3 trial testing it in combination with a checkpoint inhibitor against standard platinum-based chemotherapy plus a checkpoint inhibitor as first-line therapy in extensive-stage small cell lung cancer. The study is "not yet recruiting," with estimated enrollment of 530 participants (estimated)¹, and lists Overall survival of ZL-1310 with IO compared to chemo with IO [time frame: up to approximately 3 years]¹ as the primary outcome.
• A separate observational study will evaluate Xanomeline and Trospium Chloride Capsules (KarXT) in Chinese adult participants with schizophrenia who meet ICD-10 diagnostic criteria², sponsored by Zai Lab. The study is "not yet recruiting," plans to enroll 250 participants (estimated)², and will track KarXT treatment pattern, schizophrenia treatment decisions and compliance in the real-world setting² over a total duration of up to 17 weeks.